Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALKBH3 | Q96Q83 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.34 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.33 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.33 |
| ▸ | AHR | P35869 | 3/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 3/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5887035 | 0.84 | ALKBH3 (0.43) | ALKBH3PTGS2AHRMAOBPTGS1 | |
| SCHEMBL5887168 | 0.81 | RAD51 (0.39) | PTGS2SLC6A3PTGS1EGFR | |
| SCHEMBL5887629 | 0.75 | ALKBH3 (0.46) | ALKBH3PTGS2AHRSLC6A3MAOB | |
| SCHEMBL5887235 | 0.70 | ALKBH3 (0.36) | ALKBH3PTGS2AKR1C3AKR1C2AHR | |
| SCHEMBL5887446 | 0.68 | ALKBH3 (0.39) | ALKBH3AKR1C3AKR1C2AHRSLC6A3 | |
| SCHEMBL5887325 | 0.68 | AHR (0.33) | ALKBH3AKR1C3AKR1C2AHRSLC6A3 | |
| SCHEMBL5887140 | 0.65 | LTA4H (0.44) | PTGS1ESR1 | |
| SCHEMBL5887087 | 0.65 | RAD51 (0.41) | ALKBH3SLC6A3PTGS1ESR1EGFR | |
| SCHEMBL5887411 | 0.65 | AHR (0.41) | ALKBH3AHR | |
| SCHEMBL1047370 | 0.65 | AHR (0.70) | ALKBH3AKR1C2AHRMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7037931-B2 | Corticotropin releasing factor moderator; analgesics; drug abruse, drug dependency; schizophrenia | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-05-02 | — | — | US | disclosed |
| US-20050026903-A1 | CCK-1 receptor modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-03 | — | — | US | disclosed |
| US-20050020565-A1 | Pyrazole compound; gastrointestinal disorders; central nervous system disorders | JONES TODD K (US) | 2005-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020565-A1 | Pyrazole compound; gastrointestinal disorders; central nervous system disorders | CCKAR, CCKBR, NPY1R | ALKBH3 3753/4885PTGS2 2354/4885AKR1C3 608/4885 |
| US-20050026903-A1 | CCK-1 receptor modulators | CCKAR, CCKBR, GLP1R | ALKBH3 3208/4885PTGS2 1689/4885AKR1C3 790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.